The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia

Roger S. McIntyre; David G. Daniel; Eduard Vieta; I. Laszlovszky; Pascal Goetghebeur; Willie Earley; Mehul Patel

doi:10.1017/s109285292200013x

Back

The efficacy of cariprazine on cognition: a post hoc analysis from phase II/III clinical trials in bipolar mania, bipolar depression, and schizophrenia

Article 2022 en

Abstract

1 min read

These post hoc analyses provide preliminary evidence of greater improvements for cariprazine vs placebo across cognitive measures in patients with bipolar I depression and mania, and schizophrenia, suggesting potential benefits for cariprazine in treating cognitive symptoms.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2020

156 The Broad Efficacy of Cariprazine Across Symptoms in Patients with Bipolar I Disorder: Post Hoc Analysis of Randomized, Placebo-Controlled Trials

Lakshmi N. Yatham, Eduard Vieta, Roger S. McIntyre, Rakesh K. Jain, Willie Earley, Mehul Patel

Article2015

Effect of cariprazine across the symptoms of mania in bipolar I disorder: Analyses of pooled data from phase II/III trials

Eduard Vieta, Suresh Durgam, Kaifeng Lu, Adam Ruth, M. Debelle, Stephen R. Zukin

Article2024

Impact of Predominant Polarity on Cariprazine Efficacy in Patients with Bipolar I Disorder: A Pooled Analysis

Eduard Vieta, Jun Yu, Huy‐Binh Nguyen, Lauren C. Aronin

Article2021

The efficacy of cariprazine on function in patients with bipolar depression: a <i>post hoc</i> analysis of a randomized controlled trial

Eduard Vieta, Joseph R. Calabrese, Jessica Whelan, Mauricio Tohen, Willie Earley

Article2020

Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial

Lakshmi N. Yatham, Eduard Vieta, Willie Earley